Kaitlyn Shank

1.6k total citations
19 papers, 555 citations indexed

About

Kaitlyn Shank is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Kaitlyn Shank has authored 19 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Hematology and 5 papers in Genetics. Recurrent topics in Kaitlyn Shank's work include Acute Myeloid Leukemia Research (7 papers), Epigenetics and DNA Methylation (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Kaitlyn Shank is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Epigenetics and DNA Methylation (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Kaitlyn Shank collaborates with scholars based in United States, Israel and Switzerland. Kaitlyn Shank's co-authors include Ross L. Levine, Ari Melnick, Cem Meydan, Maria Kleppe, James E. Bradner, Alan H. Shih, Matthew D. Keller, Neha Bhagwat, Raajit K. Rampal and Francine E. Garrett-Bakelman and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kaitlyn Shank

18 papers receiving 554 citations

Peers

Countries citing papers authored by Kaitlyn Shank

Since Specialization

Citations

This map shows the geographic impact of Kaitlyn Shank's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaitlyn Shank with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaitlyn Shank more than expected).

Fields of papers citing papers by Kaitlyn Shank

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaitlyn Shank. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaitlyn Shank. The network helps show where Kaitlyn Shank may publish in the future.

Co-authorship network of co-authors of Kaitlyn Shank

This figure shows the co-authorship network connecting the top 25 collaborators of Kaitlyn Shank. A scholar is included among the top collaborators of Kaitlyn Shank based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaitlyn Shank. Kaitlyn Shank is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Identification of Immune Checkpoint Inhibitor–Induced Diabetes 2024 ·JAMA Oncology ·(unknown), Kaitlyn Shank, Aaron J. Deutsch, (unknown), Natalia Chamorro-Pareja, (unknown), (unknown), (unknown), (unknown), Alexandra–Chloé Villani, Jose C. Florez, Alexander Gusev, Kerry L. Reynolds, Karen K. Miller, Miriam S. Udler, Meghan E. Sise, Michelle Rengarajan	9
2	Transition to self-management among emerging adults with type 1 diabetes: a mixed methods study 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Kaitlyn Shank, (unknown), Liane J. Tinsley, Katharine C. Garvey, Lori M. Laffel	0
3	Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes. 2023 ·Journal of Clinical Oncology ·(unknown), Kaitlyn Shank, (unknown), (unknown), Leyre Zubiri, Alexandra–Chloé Villani, Kerry L. Reynolds, Michelle Rengarajan	2
4	Developing a Professional Identity as a Change Agent Early in Medical School: the Students’ Voice 2019 ·Journal of General Internal Medicine ·(unknown), Kaitlyn Shank, (unknown), Jed D. Gonzalo	19
5	LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone 2018 ·HemaSphere ·Jonas S. Jutzi, Maria Kleppe, Jennifer Dias, (unknown), Kaitlyn Shank, Julie Teruya‐Feldstein, (unknown), Christine Dierks, Hugh Young Rienhoff, Ross L. Levine, Heike L. Pahl	78
6	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2 - and TET2 -Mutant Acute Myeloid Leukemia 2017 ·Cancer Discovery ·Alan H. Shih, Cem Meydan, Kaitlyn Shank, Francine E. Garrett-Bakelman, Patrick S. Ward, Andrew M. Intlekofer, Abbas Nazir, Eytan M. Stein, Kristina M. Knapp, Jacob L. Glass, Jeremy Travins, (unknown), Camelia Gliser, Christopher E. Mason, Katharine Yen, Craig B. Thompson, Ari Melnick, Ross L. Levine	71
7	Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity 2017 ·Cancer Cell ·Hiroyoshi Kunimoto, Cem Meydan, Abbas Nazir, (unknown), Kaitlyn Shank, Franck Rapaport, (unknown), Elodie Pronier, Sara C. Meyer, Francine E. Garrett-Bakelman, Martin S. Tallman, Ari Melnick, Ross L. Levine, Alan H. Shih	62
8	Evaluation of Combined Extracorporeal Life Support and Continuous Renal Replacement Therapy on Hemodynamic Performance and Gaseous Microemboli Handling Ability in a Simulated Neonatal ECLS System 2017 ·Artificial Organs ·Kaitlyn Shank, (unknown), Shigang Wang, (unknown), Allen R. Kunselman, (unknown), Lucas R. Celant, (unknown)	3
9	Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells 2017 ·Blood ·Hiroyoshi Kunimoto, Anna Sophia McKenney, Cem Meydan, Kaitlyn Shank, Abbas Nazir, Franck Rapaport, Benjamin H. Durham, Francine E. Garrett-Bakelman, Elodie Pronier, Alan H. Shih, Ari Melnick, Jayanta Chaudhuri, Ross L. Levine	16
10	Evaluation of Hemodynamic Performance of a Combined ECLS and CRRT Circuit in Seven Positions With a Simulated Neonatal Patient 2017 ·Artificial Organs ·(unknown), Kaitlyn Shank, Shigang Wang, (unknown), Allen R. Kunselman, (unknown), Lucas R. Celant, (unknown)	9
11	Cooperative Epigenetic Remodeling By TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity 2016 ·Blood ·Hiroyoshi Kunimoto, Cem Meydan, Abbas Nazir, Kaitlyn Shank, (unknown), Franck Rapaport, Elodie Pronier, Ari Melnick, Ross L. Levine, Alan H. Shih	8
12	Lysine-Specific Histone Demethylase, LSD1, (KDM1A) As a Novel Therapeutic Target in Myeloproliferative Neoplasms 2015 ·Blood ·Maria Kleppe, Kaitlyn Shank, Efthymia Papalexi, (unknown), Ross L. Levine	4
13	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis 2015 ·The Journal of Experimental Medicine ·Aaron D. Viny, Christopher J. Ott, Barbara Spitzer, Martín A. Rivas, Cem Meydan, Efthymia Papalexi, Dana Yelin, Kaitlyn Shank, Jaime M. Reyes, April Chiu, Yevgeniy Romin, Vitaly Boyko, Swapna Thota, Jaroslaw P. Maciejewski, Ari Melnick, James E. Bradner, Ross L. Levine	113
14	Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis 2015 ·Blood ·Aaron D. Viny, Christopher J. Ott, Barbara Spitzer, Martín A. Rivas, Cem Meydan, Efthymia Papalexi, Dana Yelin, Kaitlyn Shank, Jaime M. Reyes, April Chiu, Swapna Thota, Jaroslaw P. Maciejewski, Ari Melnick, James E. Bradner, Ross L. Levine	2
15	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis 2015 ·The Journal of Cell Biology ·Aaron D. Viny, Christopher J. Ott, Barbara Spitzer, Martín A. Rivas, Cem Meydan, Efthymia Papalexi, Dana Yelin, Kaitlyn Shank, Jaime M. Reyes, April Chiu, Yevgeniy Romin, Vitaly Boyko, Swapna Thota, Jaroslaw P. Maciejewski, Ari Melnick, James E. Bradner, Ross L. Levine	3
16	Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms 2014 ·Blood ·Neha Bhagwat, Priya Koppikar, Matthew D. Keller, Sachie Marubayashi, Kaitlyn Shank, Raajit K. Rampal, Jun Qi, Maria Kleppe, Hardik J. Patel, Smit Shah, Tony Taldone, James E. Bradner, Gabriela Chiosis, Ross L. Levine	84
17	AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo 2014 ·Blood ·Alan H. Shih, Kaitlyn Shank, Cem Meydan, Andrew M. Intlekofer, Patrick S. Ward, Craig B. Thompson, Ari Melnick, Jeremy Travins, (unknown), Camelia Gliser, (unknown), Ross L. Levine	24
18	Mathematical Optimization of JAK Inhibitor Dose and Scheduling for MPN Patients 2014 ·Blood ·Kaitlyn Shank, Priya Koppikar, Neha Bhagwat, Matthew D. Keller, Franziska Michor, Ross L. Levine, (unknown)	1
19	Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis 2013 ·Blood ·Neha Bhagwat, Matthew D. Keller, Raajit K. Rampal, Kaitlyn Shank, Elisa de Stanchina, Kristine Rose, Dereck D. Amakye, Ross L. Levine	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact